-
公开(公告)号:US09796752B2
公开(公告)日:2017-10-24
申请号:US14778006
申请日:2014-03-18
发明人: Satoshi Komoriya , Yasuhiro Nakagami , Emiko Hatano , Takashi Ohnuki , Kayoko Masuda , Mayumi Iizuka , Yasunori Ono
IPC分类号: C07J71/00 , C12R1/785 , C12P33/00 , C12P33/06 , C12R1/645 , C12P15/00 , C12P17/02 , C07J63/00 , C12N1/14 , C12P33/02 , C12P33/20
CPC分类号: C07J71/001 , C07J63/008 , C12N1/14 , C12P15/00 , C12P17/02 , C12P33/00 , C12P33/02 , C12P33/06 , C12P33/20 , C12R1/645 , C12R1/785
摘要: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway. The present invention provides terpenoid derivative A represented by the following formula (I):
-
公开(公告)号:US10208082B2
公开(公告)日:2019-02-19
申请号:US15510208
申请日:2015-09-09
发明人: Yuji Kasuya , Yasuhiro Nakagami , Emiko Hatano , Tatsuya Inoue , Kazuhiro Yoshida , Satoshi Komoriya , Yoko Murakami , Masaru Iwasaki , Atsunobu Sakamoto , Kayoko Masuda , Masako Minami , Mayumi Iizuka , Yasunori Ono , Takashi Ohnuki
摘要: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
-
3.
公开(公告)号:US20190233466A1
公开(公告)日:2019-08-01
申请号:US16277861
申请日:2019-02-15
发明人: Yuji Kasuya , Yasuhiro Nakagami , Emiko Hatano , Tatsuya Inoue , Kazuhiro Yoshida , Satoshi Komoriya , Yoko Murakami , Masaru Iwasaki , Atsunobu Sakamoto , Kayoko Masuda , Masako Minami , Mayumi Iizuka , Yasunori Ono , Takashi Ohnuki
摘要: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
-
公开(公告)号:US20180016298A1
公开(公告)日:2018-01-18
申请号:US15704856
申请日:2017-09-14
发明人: Satoshi Komoriya , Yasuhiro Nakagami , Emiko Hatano , Takashi Ohnuki , Kayoko Masuda , Mayumi Iizuka , Yasunori Ono
IPC分类号: C07J71/00 , C12R1/645 , C12P33/20 , C12P33/06 , C12P33/02 , C12P33/00 , C12P17/02 , C12P15/00 , C12N1/14 , C12R1/785 , C07J63/00
CPC分类号: C07J71/001 , C07J63/008 , C12N1/14 , C12P15/00 , C12P17/02 , C12P33/00 , C12P33/02 , C12P33/06 , C12P33/20 , C12R1/645 , C12R1/785
摘要: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway. The present invention provides terpenoid derivative A represented by the following formula (I):
-
公开(公告)号:US10808006B2
公开(公告)日:2020-10-20
申请号:US16277861
申请日:2019-02-15
发明人: Yuji Kasuya , Yasuhiro Nakagami , Emiko Hatano , Tatsuya Inoue , Kazuhiro Yoshida , Satoshi Komoriya , Yoko Murakami , Masaru Iwasaki , Atsunobu Sakamoto , Kayoko Masuda , Masako Minami , Mayumi Iizuka , Yasunori Ono , Takashi Ohnuki
摘要: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
-
公开(公告)号:US10253060B2
公开(公告)日:2019-04-09
申请号:US15704856
申请日:2017-09-14
发明人: Satoshi Komoriya , Yasuhiro Nakagami , Emiko Hatano , Takashi Ohnuki , Kayoko Masuda , Mayumi Iizuka , Yasunori Ono
IPC分类号: C12N1/14 , C07J63/00 , C07J71/00 , C12P15/00 , C12P17/02 , C12P33/00 , C12P33/02 , C12P33/06 , C12P33/20 , C12R1/645 , C12R1/785
摘要: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway. The present invention provides terpenoid derivative A represented by the following formula (I):
-
7.
公开(公告)号:US20170260228A1
公开(公告)日:2017-09-14
申请号:US15510208
申请日:2015-09-09
发明人: Yuji Kasuya , Yasuhiro Nakagami , Emiko Hatano , Tatsuya Inoue , Kazuhiro Yoshida , Satoshi Komoriya , Yoko Murakami , Masaru Iwasaki , Atsunobu Sakamoto , Kayoko Masuda , Masako Minami , Mayumi Iizuka , Yasunori Ono , Takashi Ohnuki
CPC分类号: C07J71/001 , A61K9/0048 , A61K9/1647 , A61K9/204 , A61K31/58 , A61P27/02 , C07J63/008 , Y02A50/473
摘要: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
-
-
-
-
-
-